Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Retained Earnings (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Retained Earnings for 5 consecutive years, with -$1.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 11.59% year-over-year to -$1.5 billion; the TTM value through Mar 2026 reached -$1.5 billion, down 11.59%, while the annual FY2025 figure was -$1.5 billion, 17.52% down from the prior year.
  • Retained Earnings hit -$1.5 billion in Q1 2026 for Phathom Pharmaceuticals, down from -$1.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$570.0 million in Q1 2022 and bottomed at -$1.5 billion in Q1 2026.
  • Average Retained Earnings over 5 years is -$1.0 billion, with a median of -$1.0 billion recorded in 2024.
  • Year-over-year, Retained Earnings tumbled 39.98% in 2024 and then decreased 11.59% in 2026.
  • Phathom Pharmaceuticals' Retained Earnings stood at -$727.1 million in 2022, then fell by 27.73% to -$928.7 million in 2023, then tumbled by 36.0% to -$1.3 billion in 2024, then fell by 17.52% to -$1.5 billion in 2025, then dropped by 2.05% to -$1.5 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.5 billion, -$1.5 billion, and -$1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.